DNA损伤修复基因变异在三阴性乳腺癌辅助治疗中的应用价值
研究纳入2009年6月至2015年10月中国医学科学院肿瘤医院149例早期三阴性乳腺癌术后标本,采用二代测序分析DDR基因变异与含铂方案辅助化疗疗效的相关性。全组DDR基因突变率为97.3%(145/149),DDR突变型与野生型5年DFS率分别为85.4%和75.0%,无统计学差异(P=0.825)。结论认为DDR基因突变在TNBC中普遍存在,能否作为铂类治疗生物标志物尚需更多临床研究论证。
要点
- 149例早期TNBC中DDR基因突变率为97.3%(145/149),中位突变数4个。
- DDR突变型与野生型5年DFS率85.4%对75.0%,无统计学差异(P=0.825)。
- TCb组PIK3CA突变者5年DFS率71.4%低于野生型88.1%(P=0.037)。
核心结论
- DDR基因突变在TNBC中普遍存在,DDR突变能否成为指导铂类药物治疗的有效生物标志物尚需更多临床研究加以论证。
研究设计与样本
- 采用二代测序对2009年6月至2015年10月中国医学科学院肿瘤医院早期TNBC术后标本进行基因检测。
- 149例患者成功获得NGS检测结果,其中TCb组74例、EC-T组75例。
- 生存分析采用Kaplan-Meier法和Log rank检验,影响因素分析采用Cox比例风险回归模型。
主要发现
- 全组DDR基因突变率为97.3%(145/149),中位基因突变数为4个。
- DDR基因突变与野生型患者5年DFS率分别为85.4%和75.0%(P=0.825)。
- HRR通路突变人群中TCb组与EC-T组5年DFS率分别为84.6%和84.9%(P=0.554)。
- TCb组中HRR通路存在突变与无突变患者5年DFS率分别为84.9%和85.0%(P=0.751)。
- TCb组PIK3CA突变患者5年DFS率71.4%低于野生型88.1%(P=0.037),EC-T组KMT2D突变患者5年DFS率76.9%低于野生型86.8%(P=0.039)。
关键数值与推荐
- 存在突变的DDR通路数量以及DDR基因突变数与预后无关(均P>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- DDR突变是否能成为指导铂类药物治疗的有效生物标志物尚需更多临床研究加以论证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the correlation between adjuvant chemotherapy with platinum-containing regimens and DNA damage repair (DDR) defects in early-stage triple negative breast cancer (TNBC), and to provide a basis for precise treatment of TNBC. Methods: Next-generation sequencing (NGS) testing was performed on postoperative breast cancer specimens selected from the Cancer Hospital of Chinese Academy of Medical Sciences from June 2009 to October 2015 to analyze the correlation between DDR gene variants and the efficacy of adjuvant chemotherapy with TNBC platinum-containing regimens, and thus to screen the superior population for adjuvant chemotherapy with TNBC platinum-containing regimens. The study used t-test, χ(2) test, Fisher's exact test, rank sum test and multifactorial logistic analysis to assess the associations between mutated genes and clinicopathological characteristics and prognosis, and Log-rank test and Cox proportional risk model were used for survival and correlation analysis. Results: NGS results were successfully obtained in 149 patients (74 in the platinum-containing group and 75 in the platinum-free group), with a 97.3% (145/149) DDR gene mutation rate and a median number of 4 mutations in all patients. 5-year disease-free survival (DFS) was 85.4% and 75.0% for patients with DDR gene mutations and DDR gene wild-type, respectively, without statistical difference (P=0.825). The 5-year DFS rates of patients with homologous recombination repair (HRR) pathway mutation were 84.6% in platinum-containing (TCb) group and 84.9% in platinum-free (EC-T) group (P=0.554), respectively. The 5-year DFS rates of patients with and without mutations in the platinite-containing HRR pathway were 84.9% and 85.0%, respectively (P=0.751). The number of DDR pathways with mutations and the number of DDR gene mutations were not associated with prognosis (both P>0.05). PIK3CA mutation patients in TCb group had a worse prognosis than wild-type patients (5-year DFS were 71.4% and 88.1%, P=0.037), and KMT2D mutation patients in EC-T group had a worse prognosis than wild-type patients (5-year DFS were 76.9% and 86.8%, P=0.039). Conclusions: DDR gene variation is common in TNBC, more clinical studies are needed to prove whether DDR variation can serve as effective biomarkers for treatment with platinum. 目的: 探讨早期三阴性乳腺癌(TNBC)含铂方案辅助化疗与DNA损伤修复(DDR)缺陷的相关性。 方法: 采用二代测序(NGS)方法对2009年6月至2015月10月中国医学科学院肿瘤医院的早期TNBC术后标本进行基因检测,分析DDR基因突变与含铂方案辅助化疗疗效的相关性。生存分析采用Kaplan-Meier法和Log rank检验,影响因素分析采用Cox比例风险回归模型。 结果: 149例患者成功获得NGS检测结果(其中TCb组74例,EC-T组75例),全组患者中DDR基因突变率达97.3%(145/149),中位基因突变数为4个。DDR基因突变与DDR基因野生型患者的5年无病生存(DFS)率分别为85.4%和75.0%(P=0.825)。同源重组修复(HRR)通路突变人群中,TCb组与EC-T组患者的5年DFS率分别为84.6%和84.9%(P=0.554);TCb组中HRR通路存在基因突变与无突变患者的5年DFS率分别为84.9%和85.0%(P=0.751)。存在突变的DDR通路数量以及DDR基因突变数与预后无关(均P>0.05)。TCb组PIK3CA突变患者较野生型患者预后更差(5年DFS率分别为71.4%和88.1%,P=0.037),EC-T组中KMT2D突变较野生型患者的预后更差(5年DFS率分别为76.9%和86.8%,P=0.039)。 结论: DDR基因突变在TNBC中普遍存在,DDR突变是否能成为指导铂类药物治疗的有效生物标志物尚需更多临床研究加以论证。.
引用
- Wang X, Yue J, Kang YK, et al. [Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer]. Zhonghua Zhong Liu Za Zhi. 2023. PMID: 37805443. doi:10.3760/cma.j.cn112152-20220912-00612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。